154 related articles for article (PubMed ID: 11805337)
1. Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Halmos G; Schally AV
Proc Natl Acad Sci U S A; 2002 Jan; 99(2):961-5. PubMed ID: 11805337
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
Halmos G; Schally AV; Kahan Z
Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
[TBL] [Abstract][Full Text] [Related]
4. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.
Kovacs M; Schally AV; Csernus B; Rekasi Z
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1829-34. PubMed ID: 11172036
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Kovacs M; Schally AV
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12197-202. PubMed ID: 11593037
[TBL] [Abstract][Full Text] [Related]
6. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Horvath JE; Bajo AM; Schally AV; Kovacs M; Herbert F; Groot K
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15048-53. PubMed ID: 12409615
[TBL] [Abstract][Full Text] [Related]
9. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
Lamharzi N; Halmos G; Jungwirth A; Schally AV
Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary.
Collado B; Carmena MJ; Cortés J; Schally AV; Prieto JC
Int J Oncol; 2004 Mar; 24(3):725-30. PubMed ID: 14767559
[TBL] [Abstract][Full Text] [Related]
11. GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects.
Murase M; Uemura T; Gao M; Inada M; Funabashi T; Hirahara F
Endocr J; 2005 Feb; 52(1):131-7. PubMed ID: 15758569
[TBL] [Abstract][Full Text] [Related]
12. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
Kovacs M; Schally AV; Csernus B; Busto R; Rekasi Z; Nagy A
J Neuroendocrinol; 2002 Jan; 14(1):5-13. PubMed ID: 11903807
[TBL] [Abstract][Full Text] [Related]
13. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
Buchholz S; Seitz S; Schally AV; Engel JB; Rick FG; Szalontay L; Hohla F; Krishan A; Papadia A; Gaiser T; Brockhoff G; Ortmann O; Diedrich K; Köster F
Int J Oncol; 2009 Oct; 35(4):789-96. PubMed ID: 19724914
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
16. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
Tang X; Yano T; Osuga Y; Matsumi H; Yano N; Xu J; Wada O; Koga K; Kugu K; Tsutsumi O; Schally AV; Taketani Y
J Clin Endocrinol Metab; 2002 Aug; 87(8):3721-7. PubMed ID: 12161501
[TBL] [Abstract][Full Text] [Related]
17. Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Rozsa B; Nadji M; Schally AV; Dezso B; Flasko T; Toth G; Mile M; Block NL; Halmos G
Prostate; 2011 Apr; 71(5):445-52. PubMed ID: 20859992
[TBL] [Abstract][Full Text] [Related]
18. Actions of gonadotropin-releasing hormone analogues in pituitary gonadotrophs and their modulation by ovarian steroids.
Weiss JM; König SJ; Polack S; Emons G; Schulz KD; Diedrich K; Ortmann O
J Steroid Biochem Mol Biol; 2006 Oct; 101(2-3):118-26. PubMed ID: 16891115
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
Lamharzi N; Schally AV; Koppán M
Regul Pept; 1998 Oct; 77(1-3):185-92. PubMed ID: 9809814
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
